• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

CGM: Redefining Type 2 Diabetes Management

Opinion
Video

A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.

Video content above is prompted by the following:

  • What are the primary barriers to achieving early and consistent glycemic control in T2D patients?
  • How can CGM technology help clinicians address therapeutic inertia in diabetes care?
  • What role does CGM play in reducing the time patients spend with suboptimal glucose management?
  • How can managed care organizations support earlier adoption of CGM in newly diagnosed T2D patients?
Related Videos
Dr Sundar Jagannath
Dr Muhammad Faizan
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.